FDA Approves Biosimilar Trastuzumab-dkst for Breast and Stomach Cancers
Ogivri was granted FDA approval to treat HER2 breast and gastric or gastroesophageal junction adenocarcinoma cancers.
Stomach Cancer
Breath Test Might Assist Detection of Stomach and Esophageal Cancers
Research presented at the 2017 European Cancer Congress describes the potential of a noninvasive diagnostic test for esophageal and gastric cancers that measures chemicals in the breath.
Gene Activity Predicts Patient Response to Inhibitor Treatment for Stomach Cancer
Measurements of copies of a single gene circulating in the bloodstream allowed scientists to identify patients with stomach cancer who were most likely to respond to treatment.
Eradicating H. pylori may reduce stomach cancer risk
The heliobacter pylori bacterium is the main cause of stomach ulcers, and it also a known risk factor for non-cardia gastric cancer.
Botox may be safe and effective for the treatment of gastric cancer
Researchers found that the vagal nerve contributes to the growth of gastric tumors through the release of a neurotransmitter.
Genomic analysis clarifies subtypes of gastric cancer
In a massive effort to catalog the molecular causes of stomach cancer, scientists have identified four subtypes of tumors based on shared mutations and other molecular abnormalities. They say the new classification promises to advance clinical research to develop improved therapies for the third-leading cancer killer worldwide.
Cyramza approved by FDA for stomach cancer
Cyramza (ramucirumab) has been approved by the U.S. Food and Drug Administration to treat cancer of the stomach.
Existing medicines promising for stomach and bowel cancer
Stomach and bowel cancer—two of the most common cancers worldwide—could be treated with a class of medicines that are currently used to treat a blood disorder, according to new research.
Metastatic Cancer (Fact Sheet)
This fact sheet reviews common sites of cancer metastasis, methods of spread, treatment, and additional details.
Hodgkin treatment raises risk for stomach cancer
Survivors of Hodgkin lymphoma who received subdiaphragmatic radiotherapy had dose-dependent increased risk for stomach cancer, researchers discovered.
